A Novel Targeted Microtubules Transformable Nanopeptide System Yields Strong Anti‐Prostate Cancer Effects by Suppressing Nuclear Translocation of Androgen Receptors

Abstract

The extended use of androgen deprivation therapy (ADT) may often lead to the progression from castration‐sensitive prostate cancer (CSPC) to castration‐resistant prostate cancer (CRPC) in prostate cancer. To address this, it is essential to inhibit the nuclear translocation of the androgen receptor (AR) as part of an effective disease‐modifying strategy. Microtubules play a central role in facilitating AR nuclear translocation, highlighting their importance as a therapeutic target. In this regard, a designated as the targeted microtubules transformable nanopeptide system (MTN) is developed. This system is designed to disrupt microtubule structure and function through dual‐targeting of prostate‐specific membrane antigen (PSMA) and β‐tubulin. Initially, MTN targets prostate cells via PSMA and then specifically binds to β‐tubulin within microtubules, leading to the formation of nanofibers. These nanofibers subsequently induce the polymerization of microtubules, thereby disrupting AR transport. Notably, MTN exhibits efficient and prolonged suppression of prostate cancer across the spectrum from CSPC to CRPC, with a highly favorable safety profile in normal cells. These findings highlight the potential of MTN as a novel and promising approach for comprehensive prostate cancer therapy throughout its entire progression.